GPATCH2

Across TCGA pan-cancer cohorts, GPATCH2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPATCH2 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GPATCH2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GPATCH2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

HNSC, PDAC, and GBM are the cancer types where GPATCH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	0.742	0.978	.009	23	view →
PDAC	OS	Quartile	All	0.803	0.963	.009	20	view →
GBM	OS	Tertile	All	0.744	0.364	.001	12	view →
LUAD	OS	Median	III,IV	1.000	0.770	.006	10	view →
CCRCC	OS	Median	II,III,IV	0.840	0.656	.035	4	view →
LSCC	DFS	Median	III,IV	0.613	0.938	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPATCH2–HNSC (OS)

Open the HNSC breakdown →